GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO) is a leading pharmaceutical company in India that develops, manufactures, and markets a range of pharmaceutical products for various therapeutic areas. The company has a strong presence in India and a significant global footprint, with operations in more than 150 countries.
In terms of earnings, Revenue from Operations for Q3 FY23 was ₹802.3 crore, a 1.7% decrease from ₹815.92 crore in the same period last year. The Other Income, generated a total of ₹23.42 Crore to Total Revenue which jumped by 127% from the previous year same quarter.
A total of ₹153 Crore were contributed by the Employee Benefit Expense to the Total Expense, an increased of 7.4% from the same quarter last year. The Consolidated Net Profit was ₹164.56 crore, up 9.4% from ₹150.35 crore in the same quarter last year. This quarter’s earnings per share was ₹9.71.